Chronic allograft nephropathy: Pathogenesis and management of an important posttransplant complication

Progress in Transplantation

Volumn 14, Issue 2, 2004, Pages 82-88

  Aull, Meredith J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CALCINEURIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ALLOTRANSPLANTATION; BIOPSY; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG MONITORING; GRAFT REJECTION; HOSPITALIZATION; HUMAN; KIDNEY TRANSPLANTATION; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; CALCINEURIN; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RECEPTOR, ANGIOTENSIN, TYPE 2; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 6944241698     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.14.2.364008715322q80j     Document Type: Article

References (34)

1. URREA; UNOS. 2002 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992-2001. Available at: Http://www.optn.org/data/annualReport asp. Accessed November 21, 2003.
2. Cecka JM. The UNOS scientific renal transplant registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1999. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1999:1-21.
3. Ponticelli C. Progression of renal damage in chronic rejection. Kidney Int. 2000;57(suppl 75):S62-S70. (Pubitemid 30205442)
4. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723. (Pubitemid 29082898)
5. Kasiske BL, Kalil RSN, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int. 1991;40:514-524.
6. Krieger NR, Becker BN, Heisey DM, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation. 2003;75:1677-1682. (Pubitemid 36629149)
7. Takemoto SK, Cho YW, Gjertson DW. Transplant risks. In: Cecka JM, Terasaki PI, eds. Clinical Transplants. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1999:325-334.
8. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation. 2000;70:1098-1100.
9. Sijpkens YWJ, Doxiadis IIN, van Kemenade FJ, et al. Chronic rejection with or without transplant vasculopathy. Clin Transplant. 2003;17:163-170. (Pubitemid 36748460)
10. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation. 1998;66:1736-1740. (Pubitemid 29035001)
11. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation. 1994;57:68-72. (Pubitemid 24032742)
12. Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F. Role of transforming growth factor-b1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 2001;16(suppl 1):114-116. (Pubitemid 32492521)
13. Nicholson ML, Bailey E, Williams S, Harris KPG, Furness PN. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation. 1999;68:236-241. (Pubitemid 29360283)
14. Murphy GJ, Waller JR, Sandford RS, Furness PN, Nicholson ML. Randomized clinical trial of the effect of microemulsion cyclosporine and tacrolimus on renal allograft fibrosis. Br J Surg. 2003;90:680-686. (Pubitemid 36760595)
15. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 2001;59:1567-1573. (Pubitemid 32281249)
16. Dudley CRK, for the MMF "Creeping Creatinine" Study Group. MMF substitution for CsA is an effective and safe treatment of chronic allograft dysfunction; results of a multicenter randomized controlled study [abstract 41]. Am J Transplant. 2002;2(suppl 3):148.
17. Kahan BD, Knight R, Schoenberg L, et al. Ten years of siro - limus therapy for human renal transplantation: The University of Texas at Houston experience. Transplant Proc. 2003; 35(suppl 3A):25S-34S. (Pubitemid 36547913)
18. Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 2003;76:364-370. (Pubitemid 36928000)
19. Citterlo F, Scata MC, Violi P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc. 2003;35:1292-1294. (Pubitemid 36765512)
20. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of Rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation. 2003; 75:772-780. (Pubitemid 36373446)
21. Ruiz JC, Campistol JM, Mota A, et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc. 2003;35:1669-1670. (Pubitemid 37093666)
22. Amm JM, Ramamurthy G, Degala A, et al. Rapamycin substitution for calcineurin inhibitors in renal transplant recipients with chronic allograft nephropathy: A report of 57 cases [abstract 235]. Am J Transplant. 2003;3(suppl 5):211.
23. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol. 2001;12:1059-1071. (Pubitemid 32378348)
24. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit. 2002;24:53-58. (Pubitemid 34106732)
25. Lutz J, Zou H, Liu S, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation. 2003;76:508-515. (Pubitemid 37013255)
26. Muirhead N, House A, Hollomby DJ, Jevnikar AM. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc. 2003;35:2412-2414. (Pubitemid 37378019)
27. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis. 2000;35:58-63. (Pubitemid 30027241)
28. Omoto K, Tanabe K, Tokumoto T, et al. Use of candesartan cilexitil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation. 2003;76: 1170-1174. (Pubitemid 37339639)
29. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation. 2002;73:783-788. (Pubitemid 34260578)
30. El-Agroudy AE, Hassan NA, Foda MA, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-â1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol. 2003;23:300-306. (Pubitemid 37116929)
31. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-â1 in transplant patients with chronic allograft nephropathy. Kidney Int. 1999;56:714-719. (Pubitemid 29353172)
32. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-[beta]1 plasma levels in a crossover trial in renal transplant recipients. Transplantation. 2001;12:822-827. (Pubitemid 32246711)
33. Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int. 1995; 52:S112-115.
34. Murphy GJ, Taha R, Windmill DC, Metcalfe M, Nicholson ML. Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Br J Surg. 2001;88:261-266. (Pubitemid 32142716)